Jorey Chernett Acquires 12,000 Shares of Oncology Institute (NASDAQ:STLN) Stock

Oncology Institute, Inc. (NASDAQ:STLN) major shareholder Jorey Chernett purchased 12,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the transaction, the insider directly owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Oncology Institute Stock Down 1.0%

Shares of STLN traded down $0.07 during trading hours on Monday, hitting $6.38. The company’s stock had a trading volume of 310,018 shares, compared to its average volume of 1,903,016. The company has a market capitalization of $631.09 million, a price-to-earnings ratio of -21.30 and a beta of 0.39. Oncology Institute, Inc. has a 52-week low of $2.32 and a 52-week high of $7.05.

Analysts Set New Price Targets

Separately, Weiss Ratings assumed coverage on Oncology Institute in a research report on Thursday, August 6th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Oncology Institute Company Profile

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.